Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

337 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer.
Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, Pierart M, Poortmans PM, Struikmans H, Van der Hulst M, Van der Schueren E, Bartelink H. Vrieling C, et al. Among authors: poortmans pm. Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):677-85. doi: 10.1016/s0360-3016(99)00211-4. Int J Radiat Oncol Biol Phys. 1999. PMID: 10524422 Clinical Trial.
Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients?
Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, Bing Oei S, Peterse HL, Pierart M, Poortmans PM, Struikmans H, Van den Bogaert W, Bartelink H; EORTC Radiotherapy, Breast Cancer Groups. Vrieling C, et al. Among authors: poortmans pm. Eur J Cancer. 2003 May;39(7):932-44. doi: 10.1016/s0959-8049(03)00123-0. Eur J Cancer. 2003. PMID: 12706362 Clinical Trial.
Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network.
Omlin A, Amichetti M, Azria D, Cole BF, Fourneret P, Poortmans P, Naehrig D, Miller RC, Krengli M, Gutierrez Miguelez C, Morgan D, Goldberg H, Scandolaro L, Gastelblum P, Ozsahin M, Dohr D, Christie D, Oppitz U, Abacioglu U, Gruber G. Omlin A, et al. Lancet Oncol. 2006 Aug;7(8):652-6. doi: 10.1016/S1470-2045(06)70765-3. Lancet Oncol. 2006. PMID: 16887482
The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882 "boost versus no boost" trial.
Poortmans PM, Collette L, Bartelink H, Struikmans H, Van den Bogaert WF, Fourquet A, Jager JJ, Hoogenraad W, Müller RP, Dubois JB, Bolla M, Van Der Hulst M, Wárlám-Rodenhuis CC, Pierart M, Horiot JC; EORTC Radiation Oncology and Breast Cancer Groups. Poortmans PM, et al. Cancer Radiother. 2008 Nov;12(6-7):565-70. doi: 10.1016/j.canrad.2008.07.014. Epub 2008 Aug 28. Cancer Radiother. 2008. PMID: 18760649 Clinical Trial.
Are breast conservation and mastectomy equally effective in the treatment of young women with early breast cancer? Long-term results of a population-based cohort of 1,451 patients aged ≤ 40 years.
van der Sangen MJ, van de Wiel FM, Poortmans PM, Tjan-Heijnen VC, Nieuwenhuijzen GA, Roumen RM, Ernst MF, Tutein Nolthenius-Puylaert MC, Voogd AC. van der Sangen MJ, et al. Among authors: poortmans pm. Breast Cancer Res Treat. 2011 May;127(1):207-15. doi: 10.1007/s10549-010-1110-x. Epub 2010 Aug 12. Breast Cancer Res Treat. 2011. PMID: 20703938
337 results